Richard DiMarchi - Assembly Biosciences Insider

Assembly Biosciences -- USA Stock  

USD 46.64  0.11  0.24%

Director

Dr. Richard DiMarchi is Independent Director of Assembly Biosciences, Inc. Dr. DiMarchi is a cofounder of Assembly Pharmaceuticals and has served on its board since inception in 2012. Dr. DiMarchi currently holds the Cox Distinguished Professor of Biochemistry and Gill Chair in Biomolecular Sciences at Indiana University. Dr. DiMarchi was a cofounder and board member of biotechnology companies Ambrx and Marcadia, current founder of Assembly and Calibrium Biotech, and advisor to venture firms 5AM, Twilight Ventures, and others. Dr. DiMarchi retired as Group Vice President at Eli Lilly Company, where he provided leadership for more than two decades in biotechnology, endocrine research, and product development
Age: 61  Director Since 2014  Ph.D    
317-210-9311  http://www.assemblybio.com
DiMarchi previously served as a board member of the biotechnology trade group BIO, Isis and Millennium BioTherapeutics. His current research is focused on developing macromolecules with enhanced therapeutic properties through biochemical and chemical optimization, an approach he has termed chemicalbiotechnology.Dr. DiMarchi received his PhD in Biochemistry from Indiana University, and completed his postdoctoral studies at the Rockefeller University.

Richard DiMarchi Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (24.41) % which means that it has lost $24.41 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (44.36) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Showing few of many executives

DIRECTOR Since

Armand NeukermansDURECT Corporation
2001
Dennis BrownDelMar Pharmaceuticals
2013
Stephen HoffmanDicerna Pharmaceuticals
2007
Alan RubinoVericel Corporation
2005
Ruth ArnonVascular Biogenics Ltd
2007
Heidi HagenVericel Corporation
2013
George MigauskyDimension Therapeutics
2015
Dan GelvanVascular Biogenics Ltd
2005
Alfred NovakDova Pharmaceuticals
2017
Ron CohenVascular Biogenics Ltd
2015
Sean StalfortDova Pharmaceuticals
2016
Erich MohrDelMar Pharmaceuticals
2017
Peter KolchinskyDicerna Pharmaceuticals
2013
Georges GemayelDimension Therapeutics
2016
Jide ZeitlinVascular Biogenics Ltd
2008
David HoffmannDURECT Corporation
2010
Arlene MorrisDimension Therapeutics
2015
Terrence BlaschkeDURECT Corporation
2006
Lynda CranstonDelMar Pharmaceuticals
2015
William GarnerDelMar Pharmaceuticals
2013
Jecheskiel GonczarowskiVascular Biogenics Ltd
2001

Entity Summary

Assembly Biosciences, Inc. operates as a clinical stage biotechnology company. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana. Assembly Biosciences operates under Biotechnology classification in USA and traded on Nasdaq Capital Markets. It employs 79 people.Assembly Biosciences (ASMB) is traded on Nasdaq Capital Markets in USA. It is located in NEW YORK, U.S.A and employs 79 people. Assembly Biosciences is listed under Pharmaceutical Products category by Fama And French industry classification.

Assembly Biosciences Leadership Team

Uri Lopatin, President, Ph.D
Helen Kim, Director, MBA
Myron Holubiak, Director
Lee Arnold, Executive, Ph.D
Anthony Altig, Director
Richard Colonno, Executive
Graham Cooper, COO, MBA
William Ringo, Chairman, MBA
Susan Mahony, Director
Richard DiMarchi, Director, Ph.D
Miguel Barbosa, Executive, Ph.D
Thomas Rollins, Executive
Mark Auerbach, Director
Derek Small, CEO
Alan Lewis, Director, Ph.D
David Barrett, COO

Stock Performance Indicators

Did you try this?

Run Idea Breakdown Now
   

Idea Breakdown

Analyze constituents of all Macroaxis ideas. Macroaixs investment ideas are predefined, sector-focused investing themes
View All  NextLaunch Idea Breakdown

BATS Exchange Efficient Frontier

Diversify in USA Market
The main assumption in equity investing is that a higher degree of volatility (or risk) means a higher potential (or expected) return on investment. Conversely, investors who take on a low degree of risk have a low expection for return.
Diversify Portfolios
You can create optimal portfolios in USA market or optimize your existing portfolio in one of two ways: 1) For any level of risk, select the one which has the highest expected return. 2) For any expected return, select the one which has the lowest volatility.
Diversify Portfolios
Check also Trending Equities. Please also try Pair Correlation module to compare performance and examine historical correlation between any two equity instruments.